Navigation Links
Pixantrone Produces High Rates of Complete and Partial Remissions Even Among Aggressive NHL Patients With Extensive Prior Doxorubicin Treatment or Prior Rituximab Treatment
Date:6/1/2009

Panel Discussant Focuses on Longer Duration of Remission among Patients Achieving a Complete Remission with Pixantrone than Complete Remissions Achieved with Standard Chemotherapy

ORLANDO, June 2 /PRNewswire-FirstCall/ -- Therapeutics, Inc. ("CTI") (Nasdaq and MTA: CTIC) announced today that at the poster and discussion session of the Lymphoma and Plasma Cell Disorders Section at the 2009 American Society of Clinical Oncology ("ASCO") Annual Meeting, new subgroup analysis data were reviewed from the phase III EXTEND (PIX 301) clinical trial of pixantrone (the "PIX 301 EXTEND trial") demonstrating the effectiveness of pixantrone as therapy in patients with aggressive non-Hodgkin's lymphoma ("NHL") for whom anthracycline and related drugs are typically not to be used due to a high risk of cardiac toxicity, including cardiac failure.

Twenty-five of the 70 patients in the PIX 301 EXTEND trial had received prior cumulative doxorubicin doses in excess of the standard 300 mg/m2 associated with six cycles of first line CHOP (cyclophosphamide, doxorubicin, vincristine and prednisone) therapy. The median prior exposure of these patients, most of whom had received an anthracycline as part of a salvage regimen, was 386 mg/m2 (with a range of 306 mg/m2 to 778 mg/m2). Following treatment with pixantrone, ten of these 25 patients (40%) achieved a confirmed complete remission ("CR"), unconfirmed remission ("CRu") or partial remission ("PR") (CR=2, CRu= 5, 28%; PR=3, 12%) The lifetime cumulative doxorubicin equivalent dose following pixantrone was 579 mg/m2 (with a range of 361 mg/m2 to 1003 mg/m2). No patient developed a severe reduction (>=20%) in left ventricular ejection fraction (LVEF) and only one patient developed congestive heart failure (CHF). The total cumulative doxorubicin equivalent exposure per treatment cycle for all 68 patients treated with pixantrone is noted in the table below:

           Treatment 
'/>"/>
SOURCE Cell Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Pixantrone Phase 3 Data to be Presented at the 2009 American Society of Clinical Oncology (ASCO) Annual Meeting
2. Compared to Standard Therapies, Pixantrone Decreases Time to Achieve Complete Remission by 47% in Relapsed Aggressive Non-Hodgkins Lymphoma
3. Cell Therapeutics and IDIS Announce Agreement for a European Named Patient/Compassionate Use Program for Pixantrone
4. Pixantrone Increases Progression-Free Survival by 81% Compared to Standard Chemotherapeutic Agents in Phase III Relapsed Aggressive non-Hodgkins Lymphoma Trial
5. Pixantrone Pre-NDA Communication from FDA Provides Cell Therapeutics Basis to Begin Rolling NDA Submission
6. Cell Therapeutics Pixantrone Phase III (EXTEND) Pivotal Trial Successful in Achieving Primary Endpoint
7. Cell Therapeutics Announces Study Data Set Cut-off for Phase III Pivotal Pixantrone (301) Trial
8. Cell Therapeutics, Inc. (CTI) Announces Enrollment Complete in Phase III EXTEND (PIX301) Clinical Trial of Pixantrone in Patients With Second or Greater Relapse of Diffuse Large B Cell NHL
9. Pixantrone to be Studied in Phase I/II Trial for Aggressive Multiple Sclerosis
10. Pixantrone Shows Activity in a Preclinical Study of Experimental Autoimmune Myasthenia Gravis (EAMG)
11. Pixantrone Versus Doxorubicin in CHOP-R Therapy for First-line Treatment of Aggressive Non-Hodgkins Lymphoma Preliminary Results Presented at American Society of Hematology (ASH) Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... Pa. , Aug. 27, 2015  PinnacleHealth CardioVascular Institute ... and second in the United States ... new type of stent for blockages in the main artery ... within the artery and potentially less risk for stent fracture ... is a prospective, single-arm, multicenter clinical trial of the BioMimics ...
(Date:8/27/2015)... , Aug. 27, 2015  Lightwave Logic, ... the development of Next Generation Photonic Devices ... applications in high speed fiber-optic data communications and ... Lebby has been appointed to the Company,s ... in the field of optoelectronics is widely recognized ...
(Date:8/27/2015)... 27, 2015  CytomX Therapeutics, Inc., a biopharmaceutical ... cancer, today announced that Rachel Humphrey , ... of Directors, has been appointed chief medical officer. ... and AstraZeneca, and also oversaw clinical development of ... at Bristol-Myers Squibb and the development of Nexavar ...
Breaking Medicine Technology:First Pennsylvania Patient Treated in Landmark Vascular Study 2Lightwave Logic Announces the Appointment of Optoelectronics Industry Leader, Michael Lebby, Ph.D. to its Board of Directors 2Lightwave Logic Announces the Appointment of Optoelectronics Industry Leader, Michael Lebby, Ph.D. to its Board of Directors 3Immuno-Oncology Veteran Rachel Humphrey, M.D., Joins CytomX as Chief Medical Officer 2Immuno-Oncology Veteran Rachel Humphrey, M.D., Joins CytomX as Chief Medical Officer 3
... Corporation (Nasdaq: OMER ), a biopharmaceutical company ... inflammation and disorders of the central nervous system, today ... call Monday afternoon, October 25, 2010 at 4:00 p.m. ... Demopulos, M.D., chairman and chief executive officer, will provide ...
... 22 Endo Pharmaceuticals (Nasdaq: ENDP ) today announced ... Healthcare Conference on Tuesday, November 2, 2010, at 2:10 p.m. EDT. ... company,s products and development programs. There will be a ... www.endo.com under the investors section. About ...
Cached Medicine Technology:Omeros to Host Conference Call Monday, October 25 at 4:00 p.m. ET To Provide Corporate Update 2
(Date:8/27/2015)... Tenn. (PRWEB) , ... August 27, 2015 , ... ... DBA All Clear System. The agreement will enable both Johnson City, Tenn.-based firms to ... Clear System is a cloud-based safety product that caters to organizations in the financial, ...
(Date:8/27/2015)... ... , ... Florida Hospital North Pinellas, located at 1395 South Pinellas Avenue in Tarpon Springs, will ... facility will be located at US Highway 19 North and Highlands Boulevard, less than eight ... work on the project is slated to begin in September 2015. , The ...
(Date:8/27/2015)... ... August 27, 2015 , ... Since its ... grown to having twelve offices in three counties, LA, Orange and San Bernardino. ... California region. Founded by Dr. Richy Agajanian, the Oncology Institute of Hope ...
(Date:8/27/2015)... ... ... "I need a little help supporting and stabilizing myself when getting into ... "I developed this support handle to give me the extra little boost that I ... a helping hand when stepping into or out of the tub or shower. The ...
(Date:8/27/2015)... ... August 27, 2015 , ... ... CMaps Analytics, announced a new location analytics designer for SAP Lumira. , First ... wide range of maps experiences in the cloud and export native extensions for ...
Breaking Medicine News(10 mins):Health News:Banc Intranets Forms Strategic Marketing Partnership with All Clear System 2Health News:Banc Intranets Forms Strategic Marketing Partnership with All Clear System 3Health News:Banc Intranets Forms Strategic Marketing Partnership with All Clear System 4Health News:Florida Hospital North Pinellas is Opening a New Free-Standing Emergency Room in Palm Harbor 2Health News:Florida Hospital North Pinellas is Opening a New Free-Standing Emergency Room in Palm Harbor 3Health News:California’s Largest Private Oncology Practice Serves 50,000 Patients in 8 years 2Health News:Inventor and InventHelp Client Develops Bathroom Stabilization Aid (LCC-432) 2Health News:CMaps Analytics Announces New Location Intelligence Integration for SAP Lumira 2
... Delaware,s Partnership to Fight Chronic Disease (PFCD), a coalition committed ... of comprehensive health reform, hosted a breakfast meeting today where ... management and care. , , America spends ... 75 percent - or $1.7 trillion - of that spending ...
... 22 Communication Awards in 6 Months- , , ... effort to help consumers understand their health care options, Blue ... the last six months. The not-for-profit plan won awards from ... Advertisers, that acknowledge the company,s website design, marketing programs and ...
... , The event was an unmitigated success, welcoming 1012 visitors who ... , SAO PAULO, June 30 A ... South America Summit , held for the first time ... international conference and tabletop exhibition welcomed over 1000 key decision-makers in ...
... that men and women who feel sensitive to rejection based ... in having cosmetic surgery than those who are less sensitive ... people recall negative comments about their physical appearance. ... of the journal Body Image , was conducted by ...
... Agency Honored for Interactive and Marketing Effectiveness Campaigns , ... Cadient Group , the premier strategic interactive ... it was recognized for nine campaigns at the ... won five Gold Awards of Excellence in the Email ...
... medical device company Intelligent Hospital Systems (IH Systems) ... the Computerworld Honors Program Awards Gala on June ... the award in recognition of its RIVA System ... software, robotics and engineering to automate IV preparation ...
Cached Medicine News:Health News:Delaware's Partnership to Fight Chronic Disease Breakfast Highlights Promising Practices in Managing Chronic Disease Provides Solutions for Reduced Spending and Improved Patient Health 2Health News:Blue Shield of California Makes Understanding Health Care Issues Easier for Consumers 2Health News:Blue Shield of California Makes Understanding Health Care Issues Easier for Consumers 3Health News:Food Ingredients Industry Leaders Applaud the Launch of Health ingredients South America 2Health News:Food Ingredients Industry Leaders Applaud the Launch of Health ingredients South America 3Health News:Food Ingredients Industry Leaders Applaud the Launch of Health ingredients South America 4Health News:Cosmetic surgery appeals to men, women with appearance-based rejection sensitivity 2Health News:Cadient Group Wins Nine Communicator Awards 2Health News:Cadient Group Wins Nine Communicator Awards 3Health News:Intelligent Hospital Systems Receives International Award for Innovative Technology Benefiting Society 2
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: